174 related articles for article (PubMed ID: 15055301)
1. Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus.
French JE
IARC Sci Publ; 2004; (157):271-87. PubMed ID: 15055301
[TBL] [Abstract][Full Text] [Related]
2. Selection for loss of p53 function in T-cell lymphomagenesis is alleviated by Moloney murine leukemia virus infection in myc transgenic mice.
Baxter EW; Blyth K; Cameron ER; Neil JC
J Virol; 2001 Oct; 75(20):9790-8. PubMed ID: 11559812
[TBL] [Abstract][Full Text] [Related]
3. The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens.
French J; Storer RD; Donehower LA
Toxicol Pathol; 2001; 29 Suppl():24-9. PubMed ID: 11695559
[TBL] [Abstract][Full Text] [Related]
4. Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas.
Kakinuma S; Nishimura M; Kubo A; Nagai JY; Amasaki Y; Majima HJ; Sado T; Shimada Y
Mutat Res; 2005 May; 572(1-2):132-41. PubMed ID: 15790496
[TBL] [Abstract][Full Text] [Related]
5. Loss of one p53 allele results in four-fold reduction of p53 mRNA and protein: a basis for p53 haplo-insufficiency.
Lynch CJ; Milner J
Oncogene; 2006 Jun; 25(24):3463-70. PubMed ID: 16449974
[TBL] [Abstract][Full Text] [Related]
6. Loss of heterozygosity occurs via mitotic recombination in Trp53+/- mice and associates with mammary tumor susceptibility of the BALB/c strain.
Blackburn AC; McLary SC; Naeem R; Luszcz J; Stockton DW; Donehower LA; Mohammed M; Mailhes JB; Soferr T; Naber SP; Otis CN; Jerry DJ
Cancer Res; 2004 Aug; 64(15):5140-7. PubMed ID: 15289317
[TBL] [Abstract][Full Text] [Related]
7. Effect of p53 haploinsufficiency on melphalan-induced genotoxic effects in mouse bone marrow and peripheral blood.
Ranaldi R; Palma S; Tanzarella C; Lascialfari A; Cinelli S; Pacchierotti F
Mutat Res; 2007 Feb; 615(1-2):57-65. PubMed ID: 17109898
[TBL] [Abstract][Full Text] [Related]
8. Genetic pathways of two types of gastric cancer.
Tahara E
IARC Sci Publ; 2004; (157):327-49. PubMed ID: 15055305
[TBL] [Abstract][Full Text] [Related]
9. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice.
Ghebranious N; Sell S
Hepatology; 1998 Apr; 27(4):967-73. PubMed ID: 9537435
[TBL] [Abstract][Full Text] [Related]
10. Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent.
French JE; Lacks GD; Trempus C; Dunnick JK; Foley J; Mahler J; Tice RR; Tennant RW
Carcinogenesis; 2001 Jan; 22(1):99-106. PubMed ID: 11159747
[TBL] [Abstract][Full Text] [Related]
11. Generation of loss of heterozygosity and its dependency on p53 status in human lymphoblastoid cells.
Honma M
Environ Mol Mutagen; 2005; 45(2-3):162-76. PubMed ID: 15688360
[TBL] [Abstract][Full Text] [Related]
12. Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity.
Biggs PJ; Vogel H; Sage M; Martin LA; Donehower LA; Bradley A
Oncogene; 2003 May; 22(21):3288-96. PubMed ID: 12761499
[TBL] [Abstract][Full Text] [Related]
13. Gain-of-function mutations in the tumor suppressor gene p53.
van Oijen MG; Slootweg PJ
Clin Cancer Res; 2000 Jun; 6(6):2138-45. PubMed ID: 10873062
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.
Reese JS; Allay E; Gerson SL
Oncogene; 2001 Aug; 20(38):5258-63. PubMed ID: 11536039
[TBL] [Abstract][Full Text] [Related]
15. Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- transgenic mice.
Schreiner B; Baur DM; Fingerle AA; Zechner U; Greten FR; Adler G; Sipos B; Klöppel G; Hameister H; Schmid RM
Genes Chromosomes Cancer; 2003 Nov; 38(3):240-8. PubMed ID: 14506698
[TBL] [Abstract][Full Text] [Related]
16. Heterozygous Aprt mouse model: detection and study of a broad range of autosomal somatic mutations in vivo.
Vrieling H; Wijnhoven S; van Sloun P; Kool H; Giphart-Gassler M; van Zeeland A
Environ Mol Mutagen; 1999; 34(2-3):84-9. PubMed ID: 10529730
[TBL] [Abstract][Full Text] [Related]
17. Loss of p53 in benzene-induced thymic lymphomas in p53+/- mice: evidence of chromosomal recombination.
Boley SE; Anderson EE; French JE; Donehower LA; Walker DB; Recio L
Cancer Res; 2000 Jun; 60(11):2831-5. PubMed ID: 10850423
[TBL] [Abstract][Full Text] [Related]
18. Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice.
Hulla JE; French JE; Dunnick JK
Carcinogenesis; 2001 Jan; 22(1):89-98. PubMed ID: 11159746
[TBL] [Abstract][Full Text] [Related]
19. Cytogenetic and cellular events during radiation-induced thymic lymphomagenesis in the p53 heterozygous (+/-) B10 mouse.
Tanaka K; Watanabe K; Mori M; Kamisaku H; Tsuji H; Hirabayashi Y; Inoue T; Yoshida K; Aizawa S
Int J Radiat Biol; 2002 Mar; 78(3):165-72. PubMed ID: 11869471
[TBL] [Abstract][Full Text] [Related]
20. [Generation and analyses of transgenic mice containing mutant p53 transgene].
Hosokawa A
Fukuoka Igaku Zasshi; 1999 Mar; 90(3):80-7. PubMed ID: 10339928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
